15-LO-1 is an attractive pharmacological target for treatment of inflammatory respiratory diseases like asthma, rhinitis and chronic obstructive pulmonary disease
systemic delivery of cholesterol-tagged siRNAs targeting 12/15-LO has renoprotective effects under diabetic conditions and therefore can be a novel therapeutic approach for diabetic nephropathy
systemic delivery of cholesterol-tagged siRNAs targeting 12/15-LO has renoprotective effects under diabetic conditions and therefore can be a novel therapeutic approach for diabetic nephropathy
15-LOX-1 and its metabolites (13-S-hydroxyoctadecadienoic acid and 15-S-hydroxyeicosatetraenoic acid) have anti-carcinogenic effects in colorectal cancer. 15-LOX-1 is possibly of prognostic value in stage IV colon cancer survival
interruption of 12-LOX catalytic activity and the 12-hydroxyeicosatetraenoic acid signaling pathway by increasing 15-LOX metabolites may be a promising target for psoriasis therapies
under cellular conditions (low fatty acid and low oxygen concentrations), the allosteric binding of 12(S)-hydroxyeicosatetraenoic acid to 15-hLO-1 can increase the substrate specificity of 15-hLO-1 toward arachidonic acid over linoleic acid significantlysignificantly, which may have important implications in cancer progression
15 lipoxygenase 1 is abundant in asthmatic human airway epithelial cells and binds phosphatidylethanolamine-binding protein 1 (PEBP1), leading to generation of hydroperoxy-phospholipids, which drive ferroptotic cell death. 15LO1, PEBP1, and glutathione peroxidase 4 GPX4 activity drives abnormal asthmatic redox biology, to enhance type 2 inflammatory responses. In vitro, type 2 inflammatory cytokine IL-13 induces 15LO1 generation of hydroperoxy-phospholipids, which lowers intracellular GSH and increased extracellular GSSG levels. Lowering GSH further by inhibiting cystine transporter SLC7A11 enhances type 2 inflammatory protein expression and ferroptosis. Ex vivo, redox imbalances correspond to 15LO1 and SLC7A11 expression, type 2 inflammatory biomarkers, and worsen clinical outcomes
application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro. Maresin 1 (MaR1) and resolvin D1 (RvD1), 12/15-LOX-derived specialized proresolving mediators (SPMs), inhibited cytokine production of ILC2s at nanomolar concentration
when treating type 2 diabetic wild-type mice and transgenic mice ubiquitously overexpressing 15-LOX-1 with menhaden (fish) oil, there is a trend for the severity of diabetic peripheral neuropathy-related deficits to be less in the diabetic transgenic mice compared to the diabetic wild-type mice. Treating diabetic wild-type and transgenic mice with menhaden oil improves the diabetic peripheral neuropathy-related endpoints with a trend for greater improvement or protection by menhaden oil observed in the diabetic transgenic mice
production of 13-hydroxy-14,15-epoxy-eicosatrienoic acid (14,15-hepoxilin B3, 14,15-HXB3) and 13,14,15-trihydroxyeicosatrienoic acid (13,14,15-trioxilin B3, 13,14,15-TrXB3) from arachidonic acid in Escherichia coli expressing Archangium violaceum 15-LOX in presence and absence of Myxococcus xanthus epoxide hydrolase. Under the optimal conditions of 30 g cells/l, 200 mM ARA, 25°C, and initial pH 7.5, the cells convert 200 mM arachidonic acid into 192 mM 14,15-HXB3 and 100 mM 13,14,15-TrXB3 for 150 min, with conversion yields of 96% and 51%
production of 13-hydroxy-14,15-epoxy-eicosatrienoic acid (14,15-hepoxilin B3, 14,15-HXB3) and 13,14,15-trihydroxyeicosatrienoic acid (13,14,15-trioxilin B3, 13,14,15-TrXB3) from arachidonic acid in Escherichia coli expressing Archangium violaceum 15-LOX in presence and absence of Myxococcus xanthus epoxide hydrolase. Under the optimal conditions of 30 g cells/l, 200 mM ARA, 25°C, and initial pH 7.5, the cells convert 200 mM arachidonic acid into 192 mM 14,15-HXB3 and 100 mM 13,14,15-TrXB3 for 150 min, with conversion yields of 96% and 51%